Yazar "Albayrak, Fatih" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever(Bmc, 2020) Sahin, Ali; Derin, Mehmet Emin; Albayrak, Fatih; Karakas, Burak; Karagoz, YalcinIntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis. Methods: Between January 2014 and March 2019, 65 patients following-up at Sivas Cumhuriyet University (Medical Faculty Rheumatology-Internal Medicine Department) who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3 months, and these data were analyzed. Results: Forty-one (63.1%) patients used anakinra (100 mg/day) and 24 (36.9%) patients used canakinumab (150 mg/8 week). The median duration of anti-IL-1 agents use was 7 months (range, 3-30). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR) >= 60 ml/min/m(2), the median proteinuria decreased from 2390 mg/day (range, 14007200) to 890 mg/day (range, 1202750) (p = 0.008). No serious infections were detected, except in one patient. Conclusions: Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR >= 60 ml/min/m(2), but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the longterm effects of these treatments.Öğe EXPERIENCE OF ANAKINRA AND CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER AND COMPLICATED WITH AMYLOIDOSIS(BMJ PUBLISHING GROUP, 2019) Sahin, Ali; Derin, Mehmet Emin; Albayrak, Fatih; Karakas, Burak…Öğe A NEW SHAPE OF THE TREATMENT OF VASCULITIDES: SINGLE CENTER BIOLOGICAL AGENTS EXPERIENCE(BMJ PUBLISHING GROUP, 2019) Albayrak, Fatih; Derin, Mehmet Emin; Karakas, Burak; Sahin, Ali…Öğe THE POTENT WEAPON FOR RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE : RITUXIMAB EXPERIENCES(BMJ PUBLISHING GROUP, 2019) Karakas, Burak; Derin, Mehmet Emin; Albayrak, Fatih; Sahin, Ali…
